Anagenics Ltd has released a press release.
Cellmid Expects Record Sales in Q2 FY2019
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmid Appoints Exclusive New Zealand Distributor
- New Patents for Midkine Antibodies in USA and Europe
- Ikon Legal Action - Decision
- Cellmids Evolis Successfully Launched in USA stores
- Change of Registry Address: Automic P/L - Sydney Office
Later from Anagenics
- Cellmid: Appendix 4C and Notes to Appendix 4C
- Significant New Findings Published on Midkine
- Appendix 4D, Half Year Accounts and Strategy Update
- Minimum Holding Share Buy-Back
- Cellmids Evolis Registered in European Union (EU)
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics